Aurobindo Pharma Limited — PPTs, 05-11-2025: Investor Presentation

Here's a concise, retail-friendly summary:

1. **Business Performance:** Aurobindo Pharma delivered solid Q2FY26 results with revenue up 6.3% YoY to ₹8,286 Cr and Net Profit growing 3.8% to ₹848 Cr. Growth was driven by strong US, Europe, and Growth Markets performance. The ARV business surged, while API declined.

2. **Growth Drivers or Strategy:** The company is prioritizing its biosimilars pipeline, with products advancing through clinical stages and planned filings in immunology/oncology. Key strategies include expanding manufacturing capacity and global commercialization partnerships.

3. **Recent Developments:** In the US, 13 ANDAs were filed, 7 approvals received, and 6 products launched. European regulators granted key biosimilar approvals for trastuzumab and bevacizumab. Its Prolia biosimilar (BP16) completed Phase 3 and is ready for submission.

4. **Key Financial Metrics:** EBITDA increased 7.1% YoY to ₹1,678 Cr (20.3% margin). Reported EPS grew 4.4% to ₹14.61. The company holds a strong net cash position of ~US$170 million.

5. **Management Commentary / Outlook:** Management aims to accelerate its post-2028 biosimilars pipeline and invest in manufacturing. R&D spend focused on biosimilars and specialty products.